IQVIA Holdings Inc.

IQVIA Holdings Inc.

IQVNYSEHealthcare
$266.9
down -4.14 (-1.53%)

1-Year Price

+30.97% past year
IQVIA Holdings Inc. (IQV) 1-year price chart: up 30.97% from $203.79 on Oct 2025 to $266.90 on Oct 2026. Closing range $156.66 to $275.02.

EquityGlimpse Score

Overall
4.8/10
Narrow Moat

Some competitive advantages, though less durable than a wide moat.

Growth
3

Valuation, profitability, financial health, dividend and sentiment scores for IQVIA Holdings Inc. (IQV) are available to EquityGlimpse members.

Market Cap
43.93B
P/E Ratio
28.50
EPS
$7.91
52W High
$277.4
52W Low
$154.5
Volume
1.04M
Beta
1.17
Dividend Yield
—
Fair value estimate: sign up to see
Is IQV over- or undervalued? Run DCF and multiples models on EquityGlimpse.
See fair value

Key Financial Metrics

Price to Sales
2.38
Price to Book
5.96
EV/EBITDA
18.02
Free CF per Share
$11.93
Op. CF per Share
$15.44
Debt to Equity
2.49
Gross Margin
33.29%
Net Margin
8.34%

About IQVIA Holdings Inc.

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

CEO
Ari Bousbib
Industry
Medical - Diagnostics & Research
Employees
94,000
IPO Date
2013-05-09
Country
US
Website
Unlock Full Analysis

Get the complete picture on IQVIA Holdings Inc.

Sign up for EquityGlimpse to access deep fundamental data, AI reports, valuation models, and real-time tracking for IQV and 8,500+ other stocks.

30 Years of Financials
Income statements, balance sheets, and cash flows with 70+ interactive charts
AI-Powered Analysis
Generate professional research reports with 15+ AI models
DCF Valuation
Run discounted cash flow models with customizable assumptions
Portfolio Tracking
Track real-time P&L, sector allocation, and dividend projections
Earnings Intelligence
Surprise tracking, revision momentum, and whisper estimates
Insider & Congress Trades
Monitor what insiders and Congress members are buying and selling

Starting at $8.25/month. 7-day free trial. Cancel anytime.